The 14 references in paper S. Avdeev N., Z. Aisanov R., A. Belevskiy S., A. Vizel' A., S. Zyryanov K., G. Ignatova L., N. Knyazheskaya P., I. Leshchenko V., S. Ovcharenko I., A. Sinopal'nikov I., I. Stepanyan E., V. Trofimov I., С. Авдеев Н., З. Айсанов Р., А. Белевский С., А. Визель А., С. Зырянов К., Г. Игнатова Л., Н. Княжеская П., И. Лещенко В., С. Овчаренко И., А. Синопальников И., И. Степанян Э., В. Трофимов И. (2017) “Новые возможности в профилактике обострений хронической обструктивной болезни легких. Заключение группы специалистов Российского респираторного общества // New opportunities for prevention of exacerbations of chronic obstructive pulmonary disease. Russian Respiratory Society Expert Opinion” / spz:neicon:pulmonology:y:2017:i:1:p:108-113

1
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Revised 2017.www.goldcopd.org.Accessed February 26, 2017.
(check this in PDF content)
2
Bateman E.D., Ferguson G.T., Barnes N. et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study.Eur. Respir. J.2013; 42 (6): 1484–1494. DOI: 10.1183/09031936.00200212.
(check this in PDF content)
3
Singh D., Jones P.W., Bateman E.D. et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixeddose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): Пульмонология. 2017; 27 (1): 108–113. DOI: 10.18093/086930189320173273131083113 a multicentre, randomised study. BMC Pulm. Med.2014; 14: 178. DOI: 10.1186/1471-2466-14-178.
(check this in PDF content)
4
Buhl R., Maltais F., Abrahams R. et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur. Respir. J.2015; 45 (4): 969–979. DOI: 10.1183/09031936.00136014.
(check this in PDF content)
5
Decramer M., Anzueto A., Kerwin E. et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir. Med.2014; 2 (6): 472–486. DOI: 10.1016/ S2213-2600(14)70065-7.
(check this in PDF content)
6
Vogelmeier C.F., Bateman E.D., Pallante J. et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir. Med.2013; 1 (1): 51–60. DOI: 10.1016/S2213-2600(12)70052-8.
(check this in PDF content)
7
Beeh K.M., Derom E., Echave-Sustaeta J. et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat®is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler®(ENERGITO® study).Int. J. Chron. Obstruct. Pulmon. Dis.2016; 11: 193–205. DOI: 10.2147/COPD.S95055.
(check this in PDF content)
8
Singh D., Worsley S., Zhu C.Q. et al. Umeclidinium/ vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC Pulm. Med.2015; 15: 91. DOI: 10.1186/s12890-015-0092-1.
(check this in PDF content)
9
Vogelmeier С.F., Paggiaro P.L., Dorca J. et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study.Eur. Respir. J. 2016; 48 (4): 1030–1039. DOI: 10.1183/13993003.00216-2016. 15. Welte T., Miravitlles M., Hernandez P. et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009; 180 (8): 741–750. DOI:
(check this in PDF content)
10
1164/rccm.200904-0492OC. 16. Karner C., Cates C.J. Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2011; (3): CD008532. DOI: 10.1002/14651858.CD008532.pub2. 17. Singh D., Papi А., Corradi M. et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomized controlled trial. Lancet. 2016; 388: 963–973. DOI: 10.1016/S0140-6736(16)31354-X. 18. Singh D., Schröder-Babo W., Cohuet G. et al. The bronchodilator effects of extrafine glycopyrronium added to combin
(check this in PDF content)
11
Chapman K.R., Bateman E.D., Chen H. et al. QVA149 improves lung function, dyspnea, and health status independent of previously prescribed medications and COPD severity: A subgroup analysis from the SHINE and ILLUMINATE studies. J. COPD F.2015; 2 (1): 48–60. DOI: 10.15326.
(check this in PDF content)
12
Wedzicha J.A., Decramer M., Ficker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, doubleblind, parallel-group study.Lancet Respir. Med.2013; 1 (3): 199–209.
(check this in PDF content)
13
Wedzicha J.A. et al. Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD. N. Eng. J. Med.2016; 374 (23): 2222–2234. DOI: 10.1016/S2213-2600(13)70052-3.
(check this in PDF content)
14
Aaron S.D., Vandemheen K.L., Fergusson D. et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomised trial. Ann. Intern. Med. 2007; 146 (8): 545–555.
(check this in PDF content)